The Swiss drugmaker intends to launch a tender offer for the 44.2% of Genentech it doesn’t already own at $86.50 a share, a lower price than the $89 a share offer it made in July.
More: continued here
The Swiss drugmaker intends to launch a tender offer for the 44.2% of Genentech it doesn’t already own at $86.50 a share, a lower price than the $89 a share offer it made in July.
More: continued here